IL-32 as a potential biomarker and therapeutic target in skin inflammation

  • Front Immunol. 2023 Sep 1:14:1264236. doi: 10.3389/fimmu.2023.1264236.
Alexandra Wallimann  1 ,  Mirjam Schenk  1  2
Affiliations
  • 1. Christine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
  • 2. Institute of Tissue Medicine and Pathology, Experimental Pathology, University of Bern, Bern, Switzerland.
PMID: 37727785 DOI: 10.3389/fimmu.2023.1264236
Abstract

IL-32 is a recently described cytokine that performs a variety of functions under inflammatory conditions. Serum IL-32 has been shown to be elevated in several diseases, including Type 2 Diabetes, Cancer, Systemic Lupus Erythematosus, HIV Infection, and atopic diseases including Atopic Dermatitis. There are nine different isoforms of IL-32, with IL-32γ being the most biologically active one. The following review summarizes the different roles of the various IL-32 isoforms in the context of Skin Inflammation, with a focus on Atopic Dermatitis.

Keywords
CTCL; IL-32; atopic dermatitis; infection; melanoma; skin inflammation.